The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma

BMC Cancer

Catherine Pellat-Deceunynck¹  Pierre Antoine Gourraud²  Sophie de Visme²  Hervé Maisonneuve³  Cyrille Touzeau⁴  Anne Lok⁴  Stéphane Minvielle⁴  Martine Amiot⁴  Sabrina Trudel⁴  Steven Le Gouill⁴  Lina Benaniba⁴  Benoit Tessoulin⁴  Philippe Moreau⁴ 

[1] CRCINA, INSERM, CNRS, Université d’Angers, Université de Nantes;Centre d’investigation clinique (CIC) 1413, Inserm, pole hospitalo-universitaire 11 : Santé publique, Clinique des données, Centre Hospitalier Universitaire;Service d’hématologie clinique, Centre Hospitalier Departemental;Service d’hématologie clinique, Centre Hospitalier Universitaire;

关键词: Multiple myeloma;    Cohort;    Quality of life;    Pharmacoeconomy;    Epidemiology;    Drug resistance;   

DOI  :  10.1186/s12885-019-6080-8

来源: DOAJ

【 摘 要 】

Abstract Background Despite recent advances in the treatment of multiple myeloma, the disease constantly relapses and is still considered as incurable. The current knowledge about the biological mechanisms underlying resistance to the different class of drugs in multiple myeloma remains poor. The primary objective of the MYRACLE (Myeloma Resistance And Clonal Evolution) cohort, a multicenter prospective cohort of patients with multiple myeloma, is to address this limitation. We here describe the study background, design and methods used for this cohort. Methods/design All patients (> 18 year old) diagnosed with de novo or relapsed multiple myeloma and treated in two hematology department from west of France are included in the MYRACLE cohort. Patients provide a signed informed to be included in the study. All subjects are followed until refusal to participate in the study or death. The MYRACLE cohort prospectively collects data on socio-economic status, medical status, imaging, prognosis factors, MM therapies and associated events (resistance, safety issues). Patients also complete standardized quality of life questionnaires. In addition, bone marrow samples will be collected at time of diagnosis and relapses to perform biomarkers analysis and functional assays exploring mechanisms underlying drug resistance. Discussion The “real-life” MYRACLE cohort offers the opportunity to prospectively collect epidemiological, medical, QoL and biological data from MM patients during the course of the disease (at time of diagnosis and subsequent relapses). At mid-tem, this integrative cohort will be unique at producing a large variety of data that can be used to conceive the most effective personalized therapy for MM patients. Additionally, the MYRACLE cohort will allow integrating the medical care of MM patients in a health and pharmacoeconomic perspective.

【 授权许可】

Unknown